Intellia Therapeutics, Inc.

NasdaqGM:NTLA 株式レポート

時価総額：US$1.3b

Intellia Therapeutics マネジメント

マネジメント 基準チェック /24

Intellia Therapeuticsの CEO はJohn Leonardで、 Jan2018年に任命され、 の在任期間は 6.83年です。 の年間総報酬は$ 11.66Mで、 5.7%給与と94.3%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.82%を直接所有しており、その価値は$ 10.90M 。経営陣と取締役会の平均在任期間はそれぞれ6.2年と9.6年です。

主要情報

John Leonard

最高経営責任者

US$11.7m

報酬総額

CEO給与比率5.7%
CEO在任期間6.8yrs
CEOの所有権0.8%
経営陣の平均在職期間6.2yrs
取締役会の平均在任期間9.6yrs

経営陣の近況

Here's Why It's Unlikely That Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO Will See A Pay Rise This Year

Jun 06
Here's Why It's Unlikely That Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO Will See A Pay Rise This Year

Recent updates

Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)

Nov 19

Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus

Nov 11

Data Underwhelms - Intellia's Cash, Data And Competition Are A Challenging Story

Nov 05

Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity

Oct 25

Intellia - Exciting Promise Of First In-Vivo Gene Therapy Makes Bull Case

Sep 25

We're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Rate

Sep 07
We're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Rate

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 11
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Intellia Therapeutics Is Expanding The Scope Of Gene Editing (Technical Analysis)

Aug 03

Here's Why It's Unlikely That Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO Will See A Pay Rise This Year

Jun 06
Here's Why It's Unlikely That Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO Will See A Pay Rise This Year

Intellia Therapeutics Presents Promising In Vivo CRISPR Results

Jun 05

Industry Analysts Just Made A Dazzling Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Revenue Forecasts

May 14
Industry Analysts Just Made A Dazzling Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Revenue Forecasts

Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies

May 13

Intellia Therapeutics Is On The Move

Feb 29

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 24
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier

Feb 09

Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?

Feb 07
Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?

Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?

Jan 01
Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?

Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans

Oct 20
Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans

Intellia Therapeutics: Top Speculative Trade In The Biotech Space

Oct 05

Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling

Sep 01

Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?

Aug 06
Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?

Intellia Therapeutics down 12% following bottom line Q2 earnings miss

Aug 04

Intellia: Slim Hopes Of Near-Term Commercial Revenue Makes Me Bearish

Jul 28

Intellia Therapeutics: Several Catalysts Expected For H2 2022

May 12

Intellia: One Patent Ruling Turns The Industry Upside Down

Mar 09

Intellia Therapeutics: A Lot Of News Can Bring The Stock Up

Feb 25

Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022

Feb 09
Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022

Intellia: Best All-Around Gene Editing Company

Jan 27

We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth

Dec 31
We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth

Intellia Has Potential As Gene Therapy Play With Second Product Being Tested In Humans

Dec 15

Intellia Stock: Setting Up For Success

Nov 29

Intellia: A Step Closer To A Life-Changing Cure

Nov 21

CEO報酬分析

Intellia Therapeutics の収益と比較して、John Leonard の報酬はどのように変化したか？
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$522m

Jun 30 2024n/an/a

-US$509m

Mar 31 2024n/an/a

-US$486m

Dec 31 2023US$12mUS$660k

-US$481m

Sep 30 2023n/an/a

-US$462m

Jun 30 2023n/an/a

-US$453m

Mar 31 2023n/an/a

-US$430m

Dec 31 2022US$10mUS$630k

-US$474m

Sep 30 2022n/an/a

-US$442m

Jun 30 2022n/an/a

-US$400m

Mar 31 2022n/an/a

-US$369m

Dec 31 2021US$10mUS$600k

-US$268m

Sep 30 2021n/an/a

-US$229m

Jun 30 2021n/an/a

-US$185m

Mar 31 2021n/an/a

-US$149m

Dec 31 2020US$4mUS$580k

-US$134m

Sep 30 2020n/an/a

-US$120m

Jun 30 2020n/an/a

-US$116m

Mar 31 2020n/an/a

-US$109m

Dec 31 2019US$904kUS$559k

-US$100m

Sep 30 2019n/an/a

-US$90m

Jun 30 2019n/an/a

-US$89m

Mar 31 2019n/an/a

-US$86m

Dec 31 2018US$10mUS$550k

-US$85m

Sep 30 2018n/an/a

-US$90m

Jun 30 2018n/an/a

-US$83m

Mar 31 2018n/an/a

-US$76m

Dec 31 2017US$3mUS$396k

-US$68m

報酬と市場: Johnの 総報酬 ($USD 11.66M ) は、 US市場 ($USD 5.38M ) の同規模の企業の平均を上回っています。

報酬と収益: Johnの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

John Leonard (67 yo)

6.8yrs

在職期間

US$11,657,262

報酬

Dr. John M. Leonard, M. D. is an Executive Partner at Tyree & D'Angelo Partners. He serves as Director at 3T Biosciences, Inc. since October 2022. He has been Independent Director at IQVIA Holdings Inc. si...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
John Leonard
President6.8yrsUS$11.66m0.82%
$ 10.9m
Laura Sepp-Lorenzino
Executive VP & Chief Scientific Officer5.5yrsUS$4.19m0.019%
$ 254.0k
James Basta
Executive VP3.4yrsUS$3.99m0.017%
$ 232.8k
David Lebwohl
Executive VP & Chief Medical Officer4.6yrsUS$4.26m0.029%
$ 384.6k
Nessan Bermingham
Founder & Member of Scientific Advisor Board10.5yrsUS$11.27mデータなし
Rachel Haurwitz
Co-Founder10.5yrsUS$311.57kデータなし
Andrew May
Founder and Member of Scientific Advisor Boardno dataデータなしデータなし
Jennifer Doudna
Founder & Member of Scientific Advisor Boardno dataデータなしデータなし
Derrick Rossi
Founder & Member of Scientific Advisor Boardno dataデータなしデータなし
Rodolphe Barrangou
Founder & Member of Scientific Advisor Boardno dataデータなしデータなし
Luciano Marraffini
Founder & Member of Scientific Advisor Boardno dataデータなしデータなし
Erik Sontheimer
Founder & Member of Scientific Advisor Boardno dataデータなしデータなし

6.2yrs

平均在職期間

60yo

平均年齢

経験豊富な経営陣: NTLAの経営陣は経験豊富で経験豊富です（平均在職期間は6.2年）。

取締役

名称ポジション在職期間報酬所有権
John Leonard
President10.3yrsUS$11.66m0.82%
$ 10.9m
Nessan Bermingham
Founder & Member of Scientific Advisor Boardno dataUS$11.27mデータなし
Andrew May
Founder and Member of Scientific Advisor Boardno dataデータなしデータなし
Jennifer Doudna
Founder & Member of Scientific Advisor Board9.6yrsデータなしデータなし
Derrick Rossi
Founder & Member of Scientific Advisor Board9.6yrsデータなしデータなし
Rodolphe Barrangou
Founder & Member of Scientific Advisor Boardno dataデータなしデータなし
Luciano Marraffini
Founder & Member of Scientific Advisor Boardno dataデータなしデータなし
Erik Sontheimer
Founder & Member of Scientific Advisor Boardno dataデータなしデータなし
Arthur Krieg
Member of Scientific Advisory Boardno dataデータなしデータなし
Beverly Davidson
Member of Scientific Advisory Board9.8yrsデータなしデータなし
Franciscus A. G. Verwiel
Independent Chairman of the Board7.3yrsUS$499.94k0.010%
$ 134.0k
William Chase
Independent Director1.6yrsUS$996.21k0.0067%
$ 89.3k

9.6yrs

平均在職期間

61yo

平均年齢

経験豊富なボード: NTLAの 取締役会 は 経験豊富 であると考えられます ( 9.6年の平均在任期間)。